These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24857103)

  • 1. Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer.
    Lorente D; Mateo J; de Bono JS
    Am Soc Clin Oncol Educ Book; 2014; ():e197-203. PubMed ID: 24857103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
    Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
    Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analogous detection of circulating tumor cells using the AccuCyte
    van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
    Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.
    Onstenk W; Gratama JW; Foekens JA; Sleijfer S
    Cancer Treat Rev; 2013 Nov; 39(7):691-700. PubMed ID: 23683721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells: clinical validity and utility.
    Cabel L; Proudhon C; Gortais H; Loirat D; Coussy F; Pierga JY; Bidard FC
    Int J Clin Oncol; 2017 Jun; 22(3):421-430. PubMed ID: 28238187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
    Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.
    Gourdin T; Sonpavde G
    Asian J Androl; 2018; 20(3):230-237. PubMed ID: 29578115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer.
    Gorin MA; Verdone JE; van der Toom E; Bivalacqua TJ; Allaf ME; Pienta KJ
    Nat Rev Urol; 2017 Feb; 14(2):90-97. PubMed ID: 27872478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells in breast cancer: applications in personalized medicine.
    Lee JS; Magbanua MJM; Park JW
    Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.
    Parimi S; Ko JJ
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):939-949. PubMed ID: 28737470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
    Goodman OB; Fink LM; Symanowski JT; Wong B; Grobaski B; Pomerantz D; Ma Y; Ward DC; Vogelzang NJ
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1904-13. PubMed ID: 19505924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
    Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
    Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer.
    Pal SK; He M; Wilson T; Liu X; Zhang K; Carmichael C; Torres A; Hernandez S; Lau C; Agarwal N; Kawachi M; Yen Y; Jones JO
    Clin Genitourin Cancer; 2015 Apr; 13(2):130-6. PubMed ID: 25450039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.